abstract: Female @entity1573 were fed graded levels of @entity11822 to determine at what level a @entity4259 @entity137 occurred. In the first experiment a basal diet was supplemented with 0, 0.1, 1.0, 3.0, and 5.0 ppm of @entity4259 . These levels had no effect on egg production, egg weight or fertility of the eggs. Hatchability of fertile eggs was significantly decreased by 5 ppm of dietary @entity4259 . In the second experiment a basal diet was supplemented with 0, 5.0, 7.0, and 9.0 ppm of @entity4259 . Egg weight and hatchability were significantly decreased by 7 and 9 ppm, and egg production was decreased by 9 ppm of @entity4259 in the diet. When @entity11822 was added to the diet, there was a lag of 2 to 3 weeks before the @entity4259 content of the egg reflected the content of the diet. As long as the @entity4259 content of the diet remained the same, egg @entity4259 remained the same. When @entity4259 was no longer supplemented, egg @entity4259 content decreased. Two weeks after cessation of @entity11822 supplementation, egg @entity4259 was markedly reduced. Four weeks after cessation of @entity11822 supplementation, egg @entity4259 levels approached those of birds fed a basal diet continuously.

title: The toxic level of @entity11822 in the diet of laying XXXX .

entities_list: @entity4259 :: ('MESH:D012643', 'Chemical') :: ['selenium']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity']

entities_list: @entity11822 :: ('MESH:D018038', 'Chemical') :: ['selenite', 'sodium selenite']

answer: @entity1573 :: (9031,Species) :: ['chickens']


abstract: OBJECTIVE: To evaluate a @entity42837 subdermal contraceptive implant's (Uniplant; Thermex, Monaco) effect on the @entity43 . DESIGN: A prospective clinical trial. SETTING: San Borja-Arriar  n Clinical Hospital, University of Chile, School of Medicine. @entity1 (S): Normally cycling healthy @entity1 . INTERVENTION(S): Insertion of Uniplant. MAIN OUTCOME MEASURE(S): Luteinizing hormone pulse and endocrine profiles were assessed before, 48 hours after insertion, and after prolonged use of the implant. RESULT(S): Anovulation was noted in 100% of users in the first month. Seventy percent of subjects demonstrated follicular development with the absence of ovulation and an endocrine profile similar to the follicular phase: (LH pulse/8 hours 6.85 +/- 0.67, LH amplitude 3.54 +/- 0.65 mIU/mL (conversion factor to SI unit, 1.00), and E2 193 +/- 29.4 pg/mL (conversion factor to SI unit, 3.67), whereas 30% demonstrated no follicular activity with an endocrine profile similar to the luteal phase: (LH pulse/8 hours; 3.66 +/- 0.66, LH amplitude 5.76 +/- 1.73 mIU/mL, and E2 67.5 +/- 4 pg/mL. Clinical characteristics, serum gonadotropin concentration, and LH pulse characteristics failed to predict which subjects would initiate or remain devoid of follicular activity. CONCLUSION(S): Uniplant results in @entity3206 via two mechanisms: hypothalamic suppression in subjects who lack follicular development, and likely suppression of the pituitary LH surge in subjects who initiate follicular activity.

title: Neuroendocrine mechanism of XXXX in users of contraceptive subdermal implant of @entity42837 (Uniplant).

entities_list: @entity43 :: ('MESH:D010051', 'Disease') :: ['hypothalamus-pituitary-ovarian axis']

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'PATIENT']

entities_list: @entity3206 :: ('MESH:D000858', 'Disease') :: ['anovulation']

entities_list: @entity42837 :: ('MESH:C038501', 'Chemical') :: ['nomegestrol acetate']

answer: @entity3206 :: (MESH:D000858,Disease) :: ['anovulation']


abstract: @entity309 -induced @entity1494 is rare, with fewer than 25 cases reported so far. This localization may be life-threatening with a mortality rate of about 60%, most often due to massive @entity811 or @entity177 as a result of @entity1582 . We report the case of a 72-year-old @entity1 with a long history of @entity309 who developed gross @entity811 that induced severe @entity417 . Ultrasonography and tomodensitometry revealed a large mass localized in the upper part of the bladder. Cystoscopy showed a congestive inflammatory area with a large vesicoperitoneal @entity292 . Biopsies revealed @entity2783 , and immunohistochemical staining of the specimens defined the process as @entity2783 . The @entity527 were also found in the rectum, duodenum, uterus and kidneys. This case of @entity309 -induced @entity1494 is characterized by its pseudotumoral aspect and the existence ofa vesico-peritoneal @entity292 : only 2 cases have been reported so far. Treatment was symptomatic, and the @entity1 died from @entity3085 . The pseudotumoral forms of @entity2783 , including @entity1494 , deserve an early correct diagnosis. Otherwise, an incorrect diagnosis, especially @entity5 , may prompt inappropriate treatments.

title: @entity309 -induced XXXX with vesico-peritoneal @entity292 .

entities_list: @entity1 :: ('9606', 'Species') :: ['woman', 'patient']

entities_list: @entity527 :: ('MESH:D058225', 'Disease') :: ['amyloid deposits']

entities_list: @entity1494 :: ('MESH:D001745', 'Disease') :: ['AA amyloidosis of the bladder', 'amyloidosis of the bladder']

entities_list: @entity2783 :: ('MESH:D000686', 'Disease') :: ['AA amyloidosis', 'amyloidosis']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer']

entities_list: @entity177 :: ('MESH:D051437', 'Disease') :: ['multiorgan failure']

entities_list: @entity1582 :: ('MESH:D009101', 'Disease') :: ['systemic amyloidosis']

entities_list: @entity811 :: ('MESH:D006417', 'Disease') :: ['hematuria']

entities_list: @entity309 :: ('MESH:D001172', 'Disease') :: ['rheumatoid arthritis', 'Rheumatoid arthritis']

answer: @entity1494 :: (MESH:D001745,Disease) :: ['pseudotumoral AA amyloidosis of the bladder']


abstract: PURPOSE: Multiagent chemotherapy and chemohormonal therapy for @entity0 are associated with an increased risk for @entity1211 . We observed instances of arterial @entity715 in two studies of @entity0 involving multiagent chemotherapy for stages II and III disease. Our purpose in this study was to determine the incidence of this complication and whether it appeared to be related to the chemotherapy or was a random event. @entity1 AND METHODS: Episodes of arterial @entity715 events were identified from record reviews of 1,014 assessable @entity1 with @entity0 entered on two @entity5 and @entity1778 Group B protocols. Details of the kind of arterial event, when it occurred, the outcome, and the occurrence of @entity3 were analyzed. RESULTS: Thirteen (1.3%) @entity1 had an arterial @entity715 : six (5.3%) of 113 @entity1 with @entity5 and seven (0.8%) of 901 @entity1 with @entity34 . Four of these @entity1 had a peripheral arterial @entity715 and nine had @entity64 (four were fatal). All these events occurred while the @entity1 were receiving adjuvant chemotherapy. Only one additional arterial event (a @entity64 approximately four years later) has occurred in this @entity1 group after chemotherapy was completed. CONCLUSION: @entity715 is also associated with multiagent chemotherapy in @entity1 with @entity0 . The mechanism is unknown.

title: @entity715 associated with adjuvant chemotherapy for XXXX : a @entity5 and @entity1778 Group B Study.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'PATIENTS']

entities_list: @entity64 :: ('MESH:D020521', 'Disease') :: ['strokes', 'stroke']

entities_list: @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['stage III disease', 'Cancer']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastases']

entities_list: @entity715 :: ('MESH:D013927', 'Disease') :: ['Arterial thrombosis', 'thrombosis', 'thrombotic']

entities_list: @entity1211 :: ('MESH:D054556', 'Disease') :: ['venous thromboembolic complications']

entities_list: @entity34 :: ('MESH:D016609', 'Disease') :: ['stage II disease']

answer: @entity0 :: (MESH:D001943,Disease) :: ['breast carcinoma']


abstract: BACKGROUND: The quality of life (QOL) of caregivers of individuals with chronic @entity1566 may be affected by several factors. Moreover, this issue is yet to be documented fully in the literature. The purpose of this study was to evaluate the health related quality of life of spouses who act as primary caregivers of veterans with chronic @entity1566 in Iran. METHODS: The study consisted of 72 wives of 72 veterans who were categorized as spinal cord injured @entity1 based on the American @entity3510 Association (ASIA) classification. Health related quality of life was assessed by the Short Form (SF-36) Health Survey. Pearson's correlation was carried out to find any correlation between demographic variables with SF-36 dimensions. To find the effect of the factors like age, employment status, duration of care giving, education, presence or absence of @entity626 , and mechanical back @entity158 on different domains of the SF-36 health survey, Multivariate analysis of variance (MANOVA) was used. RESULTS: The mean age of the @entity1 was 44.7 years. According to the ASIA classification 88.9% and 11.1% of the veterans were paraplegic and tetraplegic respectively. Fifty percent of them had a complete injury (ASIA A) and 85% of the spouses were exclusive care givers. All of the SF-36 scores of the spouses were significantly lower than the normal population. Pearson's correlation demonstrated a negative significant correlation between both age and duration of caring with the PF domain. The number of @entity1 had a negative correlation with RE and VT. CONCLUSION: The burden of caregiving can impact the QOL of caregivers and cause health problems. These problems can cause limitations for caregiver spouses and it can lead to a decrease in the quality of given care.

title: Quality of life and the related factors in spouses of veterans with chronic XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'children', 'patients']

entities_list: @entity3510 :: ('MESH:D013124', 'Disease') :: ['Spinal Injury']

entities_list: @entity626 :: ('MESH:D020370', 'Disease') :: ['knee osteoarthritis']

entities_list: @entity1566 :: ('MESH:D013119', 'Disease') :: ['spinal cord injuries']

answer: @entity1566 :: (MESH:D013119,Disease) :: ['spinal cord injury']


abstract: BACKGROUND: The aim of the present study was to examine how liver markers are associated with @entity2690 resistance in Japanese community-dwelling adults. METHODS: This cross-sectional study included 587 @entity1 aged 58    14 (mean    standard deviation; range, 20-89) years and 755 @entity1 aged 60    12 (range, 21-88) years. The study sample consisted of 998 (74.4%) @entity28 [body mass index (BMI) <25.0 kg/m2] and 344 (25.6%) overweight (BMI >=  25 kg/m2) subjects. @entity2690 resistance was defined by homeostasis model assessment of @entity2690 resistance (HOMA-IR) of at least 2.5, and HOMA-IR and potential confounders were compared between the groups. Areas under the curve (AUC) of the receiver operating characteristic curves (ROC) were used to compare the power of these serum markers. RESULTS: In @entity28 subjects, the best marker of @entity2690 resistance was @entity493 aminotransferase (ALT)/ @entity492 aminotransferase ( @entity6571 ) ratio of 0.70 (95% confidence interval (CI), 0.63-0.77). In overweight subjects, AUC values for the ALT/ @entity6571 ratio and ALT were 0.66 (0.59-0.72) and 0.66 (0.59-0.72), respectively. Multiple linear regression analyses for HOMA-IR showed that ALT/ @entity6571 ratios were independently and significantly associated with HOMA-IR as well as other confounding factors in both @entity28 and overweight subjects. The optimal cut-off point to identifying @entity2690 resistance for these markers yielded the following values: ALT/ @entity6571 ratio of >=  0.82 in @entity28 subjects and >=  1.02 in overweight subjects. In @entity28 subjects, the positive likelihood ratio was greatest for ALT/ @entity6571 ratio. CONCLUSIONS: In @entity28 Japanese adults, ALT/ @entity6571 ratio may be the best reliable marker of @entity2690 resistance.

title: XXXX aminotransferase/ @entity492 aminotransferase ratio is the best surrogate marker for @entity2690 resistance in @entity28 Japanese adults.

entities_list: @entity28 :: ('MESH:D009765', 'Disease') :: ['non-obese']

entities_list: @entity492 :: ('CHEBI:29995', 'Chemical') :: ['aspartate']

entities_list: @entity493 :: ('CHEBI:16449', 'Chemical') :: ['alanine']

answer: @entity493 :: (CHEBI:16449,Chemical) :: ['Alanine']


abstract: BACKGROUND: @entity2 is the leading cause of @entity5 in @entity1 and @entity1 in the world, more than one-half of cases are diagnosed at a advanced stage, and the overall 5-year survival rate for @entity2 is 18%. @entity2 is divided into @entity1149 ( @entity1149 ) and @entity151 ( @entity151 ). Approximately 80%-85% of cases are @entity1149 which includes three main types: @entity420 (40%), @entity957 ( @entity957 ) (20%-30%), and @entity152 (10%). Although therapies that target driver mutations in @entity420 are showing some promise, they are proving ineffective in smoking-related @entity957 . We need pay more attention to the diagnosis and treatment of @entity957 . 18F-FDG positron emission tomography (PET)/computed tomography (CT) has emerged as an accurate staging modality in @entity2 diagnosis. The aim of this study is to investigate the role of maximum standardized uptake value (SUVmax) on PET-CT in prognosis and its correlation with clinicopathological characteristics in resectable @entity957 . METHODS: One hundred and eighty-two resectable @entity957 @entity1 who underwent PET/CT imaging between May 2005 and October 2014 were enrolled into this retrospectively study. All the enrolled @entity1 had underwent pulmonary resection with mediastinal lymph node dissection without preoperative chemotherapy or radiotherapy. Survival outcomes were analyzed using the Kaplan-Meier method and multivariate Cox proportional hazards model. Correlation between SUVmax and clinicopathological factors was analysed using Pearson correlation analysis and Spearman rank correlation analysis. RESULTS: The @entity1 were divided into two groups on the basis of SUVmax 13.0 as cutoff value, and @entity1 with SUVmax more than 13.0 had shorter median overall survival than @entity1 less than 13.0 in univariate analysis (56 months vs 87 months; P=0.022). There was remarkable correlation between SUVmax and gender, @entity5 size, @entity5 ( @entity5 ) stage, neutrophil, NLR, hemoglobin (P<0.05). Multivariate Cox analysis demonstrated that SUVmax (HR=1.714, 95%CI: 1.021-2.876, P=0.042), @entity5 stage (HR=1.677, 95%CI: 1.231-2.284, P=0.001) were independent predictors for survival. Furthermore, univariate survival analysis showed significant difference by SUVmax in @entity1 of stage I (P=0.045). CONCLUSIONS: SUVmax may be of importance prognostic factor independent of @entity5 stage, which was considerable for risk stratification in @entity1 with @entity5 stage. Besides, there was correlation between SUVmax of @entity5 and clinicopathological characteristics.   .

title: [Analysis of the Role of PET/CT SUVmax in Prognosis and Its Correlation with    Clinicopathological Characteristics in Resectable XXXX ].

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients', 'men']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'tumor-node-metastasis', 'TNM', 'cancer death', 'primary tumor']

entities_list: @entity957 :: ('MESH:D002294', 'Disease') :: ['squamous cell carcinoma', 'SCC']

entities_list: @entity2 :: ('MESH:D008175', 'Disease') :: ['Lung cancer', 'lung cancer']

entities_list: @entity1149 :: ('MESH:D002289', 'Disease') :: ['NSCLC', 'non-small cell lung carcinoma']

entities_list: @entity152 :: ('MESH:D018287', 'Disease') :: ['large cell carcinoma']

entities_list: @entity151 :: ('MESH:D055752', 'Disease') :: ['SCLC', 'small cell lung carcinoma']

entities_list: @entity420 :: ('MESH:D000230', 'Disease') :: ['adenocarcinomas', 'adenocarcinoma']

answer: @entity957 :: (MESH:D002294,Disease) :: ['Lung Squamous Cell Carcinoma']


abstract: OBJECTIVE: To evaluate the safety and efficacy of a single intra-articular injection of 2% hyaluronic acid (HA)+ @entity2656 in symptomatic @entity626 ( @entity626 ). MATERIAL AND METHODS: Pilot, multicentre, open, non-comparative study performed in eighty @entity1 with @entity158 @entity626 , of whom 79 completed the study. They received one injection of 2ml of 2% HA+0.5% @entity2656 (Day 0) and were followed-up for 6 months. On Days 0, 15, 30, 60, 90, 120, 150 and 180, @entity158 and joint function were assessed using a visual analogue scale (VAS) and WOMAC index. Efficacy and safety by investigator and @entity1 , and rescue medication, as an indirect measure of @entity158 , were also recorded. RESULTS: A significant reduction in joint @entity158 , @entity717 compared with baseline was observed at every follow-up visit (P<.001). Joint function improved by 38.7% on Day 30, reaching 47.5% on Day 180. Rescue medication use decreased from 58.2% at baseline to 2.5% on Day 90, increasing in the last visits. Efficacy and safety were positively evaluated by investigators and @entity1 . No serious adverse events were observed. Mild side effects were reported in 4 @entity1 ( @entity158 and swelling in the infiltration area). DISCUSSION: There is evidence that repeated intra-articular injections of HA improve symptoms in @entity626 . However, studies with a single injection of HA have shown mixed results. This study demonstrates that one single intra-articular injection of @entity158 and increases function in @entity1 with @entity626 over a period of at least 6 months.

title: [Efficacy and safety of a single intra-articular injection of 2% hyaluronic acid plus @entity2656 in XXXX over a 6-month period].

entities_list: @entity2656 :: ('MESH:D008353', 'Chemical') :: ['mannitol']

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity626 :: ('MESH:D020370', 'Disease') :: ['knee osteoarthritis', 'KOA']

entities_list: @entity158 :: ('MESH:D010146', 'Disease') :: ['pain', 'non-cross-linked HA reduces joint pain', 'painful', 'local pain']

entities_list: @entity717 :: ('MESH:D009069', 'Disease') :: ['stiffness and functional disability']

answer: @entity626 :: (MESH:D020370,Disease) :: ['knee osteoarthritis']


abstract: OBJECTIVE: To examine relations between maternal @entity308 (in pure and comorbid forms) and mother- @entity1 interactions, @entity1 attachment, and toddler @entity6100 and competencies. A second objective was to explore sex differences. METHOD: Sixty-nine mother- @entity1 dyads were followed from pregnancy to 30 months postpartum. @entity308 was measured at multiple times with self-report and interview assessments. Play was assessed at 4 months and attachment status at 14 months postpartum. At 30 months, mothers completed the @entity1 Behavior Checklist and @entity1 -Toddler Social and Emotional Assessment. RESULTS: Lifetime maternal @entity308 predicted less optimal mother- @entity1 interactions and insecure @entity1 attachment. However, this " @entity308 effect" was accounted for by mothers with comorbid diagnoses, who had less optimal interactions, and @entity1 with higher rates of insecurity than either mothers with @entity308 only or mothers with no psychopathology. Prenatal and postpartum @entity308 symptoms were associated with problem behaviors and lower competencies for @entity1 . In contrast, quality of early interactions predicted problem behaviors in @entity1 . CONCLUSIONS: It is important to examine the context of maternal @entity308 with respect to additional psychopathology and environmental risks. @entity308 in the presence of other psychopathology confers risk to the mother- @entity1 dyad. Consistent with previous work, risk pathways appear to differ for @entity1 and @entity1 . Early identification and prevention efforts are warranted.

title: XXXX and comorbidity: predicting early parenting, attachment security, and toddler @entity6100 and competencies.

entities_list: @entity1 :: ('9606', 'Species') :: ['child', 'Child', 'Infant', 'infants', 'girls', 'boys', 'infant']

entities_list: @entity6100 :: ('OMIM:300082', 'Disease') :: ['social-emotional problems']

entities_list: @entity308 :: ('MESH:D003866', 'Disease') :: ['Depression', 'depression', 'depressive', 'Maternal depression']

answer: @entity308 :: (MESH:D003866,Disease) :: ['Maternal depression']


abstract: INTRODUCTION: @entity32 has been identified as a hallmark of @entity5 and may be necessary for tumorgenesis and maintenance of the @entity5 state. @entity32 -related symptoms are common in those with @entity5 ; however, little is known about the relationship between symptoms and systemic @entity32 in @entity5 . The aim of the present study was to examine the relationship between symptoms and systemic @entity32 in a large cohort of @entity1 with @entity5 . METHODS: Data from an international cohort of @entity1 with @entity5 were analyzed. Symptoms and @entity1 -related outcomes were recorded using the European Organisation for Research and Treatment of @entity5 Quality of Life Questionnaire--Core Questionnaire. Systemic @entity32 was assessed using @entity1851 levels. The relationship between these symptoms and systemic @entity32 was examined using Spearman rank correlation (  ) and the Mann-Whitney U test. RESULTS: Data were available for 1,466 @entity1 across eight European countries; 1,215 @entity1 (83%) had @entity3 at study entry. The median survival was 3.8 months (interquartile range [IQR] 1.3-12.2 months). The following were associated with increased levels of @entity32 : performance status (   = .179), survival (   = .347), @entity158 (   = .154), @entity448 (   = .206), @entity73 (   = .137), @entity1353 (p= .150), fatigue (   = .197), physical dysfunction (   = .207), @entity409 (   = .176), social dysfunction (   = .132), and poor quality of life (   = .178). All were statistically significant at p < .001. CONCLUSION: The results show that the majority of @entity5 symptoms are associated with @entity32 . The strength of the potential relationship between systemic @entity32 and common @entity5 symptoms should be examined further within the context of an anti-inflammatory intervention trial.

title: The systemic inflammatory response and its relationship to @entity158 and other symptoms in XXXX .

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['Inflammation', 'inflammation']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer', 'Cancer', 'advanced cancer']

entities_list: @entity73 :: ('MESH:D003072', 'Disease') :: ['cognitive dysfunction']

entities_list: @entity409 :: ('MESH:D008107', 'Disease') :: ['role dysfunction']

entities_list: @entity448 :: ('MESH:D000855', 'Disease') :: ['anorexia']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastatic disease']

entities_list: @entity1851 :: ('1401', 'Gene') :: ['C-reactive protein']

answer: @entity5 :: (MESH:D009369,Disease) :: ['advanced cancer']


abstract: PURPOSE: In 2012-2013, a cross-sectional survey was conducted in @entity1 visiting a general practitioner for @entity293 ( @entity293 ), to estimate the annual incidence of UTIs due to antibiotic-resistant @entity526 (E. coli). METHODS: A sampling design (stratification, stages and sampling weights) was taken into account in all analyses. Urine analyses were performed for each @entity1 and centralised in one laboratory. RESULTS: Among 538 included @entity1 , urine culture confirmed @entity293 in 75.2  % of cases. @entity526 represented 82.8  % of species. Among @entity526 , resistance (I  +  R) was most common to @entity115 [38  % (95  % confidence interval 31.1-44.5)] and to @entity206 / @entity207 [18.1  % (12.0-24.1)]. Resistance to @entity2177 and @entity3524 was lower [1.9  % in both cases, (0.3-3.5)], as it was for @entity6616 [0.4 (0-1.0)] and @entity8912 (0). Extended-spectrum b-lactamase (ESBL) represented 1.6  % of @entity526 (0.2-2.9). Annual incidence rate of confirmed @entity293 was estimated at 2400 per 100,000 @entity1 (1800-3000). Incidence rates of @entity293 due to @entity3284 -resistant and ESBL-producing @entity526 were estimated at 102 per 100,000 @entity1 (75-129) and at 32 (24-41), respectively. CONCLUSIONS: ESBL had been found in a community population, and even though the rate was low, it represents a warning and confirms that surveillance should continue.

title: Incidence of XXXX and antibiotic resistance in the outpatient setting: a cross-sectional study.

entities_list: @entity6616 :: ('MESH:D009582', 'Chemical') :: ['nitrofurantoin']

entities_list: @entity115 :: ('MESH:D000658', 'Chemical') :: ['amoxicillin']

entities_list: @entity3284 :: ('D024841', 'Chemical') :: ['fluoroquinolone']

entities_list: @entity526 :: ('562', 'Species') :: ['Escherichia coli', 'E. coli']

entities_list: @entity2177 :: ('MESH:D002939', 'Chemical') :: ['ciprofloxacin']

entities_list: @entity8912 :: ('MESH:D005578', 'Chemical') :: ['fosfomycin']

entities_list: @entity3524 :: ('MESH:D002439', 'Chemical') :: ['cefotaxime']

entities_list: @entity207 :: ('MESH:D013420', 'Chemical') :: ['sulfamethoxazole']

entities_list: @entity293 :: ('MESH:D014552', 'Disease') :: ['urinary tract infection', 'UTI']

entities_list: @entity206 :: ('MESH:D014295', 'Chemical') :: ['trimethoprim']

answer: @entity293 :: (MESH:D014552,Disease) :: ['urinary tract infections']


abstract: OBJECTIVE: To analyze and summarize the characteristics of @entity13785 ( @entity13785 ) @entity1 according to the clinical description and prognosis. METHOD: Seventeen Chinese @entity1 diagnosed by acid alpha-glucosidase ( @entity12190 ) enzyme activity test were reviewed. Clinical data tables were designed. Interviews were made via phone calls. Information was collected to reach the objective. RESULT: Four of 17 @entity1 diagnosed by acid alpha-glucosidase are infantile-onset, symptoms started between 2 to 6 months after birth with increased serum @entity908 kinase and cardiac problems, with or without respiratory concerns. Other 13 @entity1 were later-onset cases, and their symptoms started between 2 to 22 years of age with increased serum @entity908 kinase. Eleven later-onset @entity1 started with @entity425 , 2 @entity1 developed @entity1576 , 2 @entity1 showed @entity1635 , and 1 @entity1 expressed increased serum @entity908 kinase with @entity409 . Just 3 of the later-onset @entity1 were treated with mechanical ventilator and adjuvant therapy, others were not. All @entity1 ' acid alpha-glucosidase ( @entity12190 ) enzyme activity analysis showed lower than 10% of normal. Fourteen @entity1 were tested by muscle biopsy pathology, and 9 of them progressed to @entity13785 ; 10 @entity1 received genetic analysis, and 6 of them had two mutations which cause the disorder. Twelve of the 17 @entity1 were interviewed successfully. In 3 of the @entity1 -onset @entity1 the disease resulted in @entity204 from @entity1576 , and 1 is still alive at the age of 1 year and 7 months. In 4 of 8 later-onset @entity1 the disease resulted in @entity204 from @entity1576 between 3 to 5 years after onset of symptoms. Three of 4 survivors had increased @entity425 , and 1 @entity1 kept alive with ventilator without any changes. Seven of 12 interviewed @entity1 died, the mortality rate was 58.3%. CONCLUSION: Glycogen storage disease @entity1605 ( @entity13785 ) present differently in the clinic. @entity1 -onset @entity13785 is mainly characterized by generalized @entity425 and obvious cardiac involvement. It's a dangerous disease, with high mortality rate. Later-onset @entity13785 is characterized by chronic proximal @entity425 and @entity1576 . @entity12190 enzyme activity analysis, muscle biopsy and genetic analysis used to support the diagnosis of @entity13785 . Prognosis of the disease depends on age of onset and respiratory muscle involvement.

title: [Clinical sequelae of 17 cases with XXXX /Pompe disease].

entities_list: @entity1 :: ('9606', 'Species') :: ['Infant', 'patients', 'patient', 'infant']

entities_list: @entity908 :: ('MESH:D003401', 'Chemical') :: ['creatine']

entities_list: @entity409 :: ('MESH:D008107', 'Disease') :: ['abnormal liver function']

entities_list: @entity1635 :: ('MESH:D012600', 'Disease') :: ['scoliosis']

entities_list: @entity425 :: ('MESH:D018908', 'Disease') :: ['muscle weakness']

entities_list: @entity13785 :: ('MESH:D006009', 'Disease') :: ['glycogen storage disease type II', 'Pompe disease']

entities_list: @entity1576 :: ('MESH:D012131', 'Disease') :: ['respiratory failure', 'respiratory insufficiency']

answer: @entity13785 :: (MESH:D006009,Disease) :: ['glycogen storage disease type II']


abstract: The histories of 386 @entity1 with untreated hydatidiform mole were reviewed to define the clinical aspects of accompanying theca @entity45 . These cysts occurred in 102 @entity1 (26.4%), with three @entity1 experiencing @entity532 . Mean cyst size at diagnosis was 7.3 cm (3-20 cm), and did not correlate with post-molar @entity1469 development. Bilateralism occurred more often in @entity1 developing post-molar @entity1469 . In @entity1 with post-molar @entity1469 , 83% (45 of 54) experienced theca lutein cyst regression and 16.7% an increase in cyst size with falling beta-hCG titers. Post-molar @entity1469 developed in 44 @entity1 . Theca lutein cyst growth occurred in 31.8% of the @entity1 with beta-hCG plateau/rise and in 4.5% with falling titers. Disappearance of theca @entity45 before diagnosis of post-molar @entity1469 occurred in 31.8%. Theca @entity45 persisted in three @entity1 for long periods (15-18 weeks) after beta-hCG regression. We conclude that theca @entity45 commonly accompany hydatidiform mole and are associated with an increased risk of post-molar @entity1469 , a risk that is higher with cyst bilateralism or severe complications of hydatidiform mole. Theca @entity45 uncommonly have serious complications; their clinical behavior does not depend entirely on changes in beta-hCG levels, as cysts may persist for long periods after beta-hCG regression.

title: The natural history of theca XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity532 :: ('MESH:D003925', 'Disease') :: ['cyst-related complications']

entities_list: @entity45 :: ('MESH:D010181', 'Disease') :: ['lutein cysts']

entities_list: @entity1469 :: ('MESH:D031901', 'Disease') :: ['trophoblastic disease']

answer: @entity45 :: (MESH:D010181,Disease) :: ['lutein cysts']


abstract: UNASSIGNED: Elevation of @entity428 ( @entity428 ) may worsen @entity1545 and neurological outcome. Studies on the use of therapeutic @entity2332 (TH) for @entity131 suggests that rapid rewarming from TH is associated with @entity428 and poorer outcomes. However, few studies describe the time course of @entity428 changes during TH/rewarming after @entity1167 ( @entity1167 ). In this study, we observed the changes in @entity428 during mild TH and rewarming after @entity1167 . Secondarily, we examined whether @entity428 is related to outcome. We studied @entity772 @entity1 resuscitated from @entity1167 , who were treated with TH and who had @entity428 monitored. Target core temperature was 34  C for 24   h and target rewarming rate was 0.25  C/h. @entity428 and cerebral perfusion pressure (CPP) were monitored during the period. Outcome was rated as cerebral performance category. In nine @entity1 , @entity428 increased during TH and rewarming (6.0 [4.0-9.0] mmHg to 16.0 [12.0-26.0] mmHg, p   =   0.008). CPP did not change during the period (83.3 [80.1-91.0] mmHg to 74.3 [52.0-87.3] mmHg). Higher @entity428 was associated with worse outcomes (p   =   0.009). All the cases with @entity428 >25   mmHg or CPP <40   mmHg died. @entity428 was observed during the rewarming period, although, some increase of @entity428 occurred even during the mild TH. @entity428 increment was higher in @entity1 with worse outcomes.

title: Intracranial Pressure Increases During Rewarming Period After Mild Therapeutic @entity2332 in @entity1167 XXXX .

entities_list: @entity1545 :: ('MESH:D020214', 'Disease') :: ['brain injury']

entities_list: @entity131 :: ('MESH:D001930', 'Disease') :: ['traumatic brain injury']

entities_list: @entity428 :: ('MESH:D019586', 'Disease') :: ['ICP', 'intracranial pressure', 'Major ICP increment', 'elevated ICP']

entities_list: @entity772 :: ('MESH:D003128', 'Disease') :: ['comatose']

entities_list: @entity1167 :: ('MESH:D006323', 'Disease') :: ['cardiac arrest', 'CA']

entities_list: @entity2332 :: ('MESH:D007035', 'Disease') :: ['hypothermia']

answer: @entity1 :: (9606,Species) :: ['Patients']


abstract: The choroid affected by the @entity7375 ( @entity7375 ) has seldom been explored by @entity3194 choroidal angiography. Five @entity1 with definite diagnosis of @entity7375 underwent this investigation. The first case had the most marked leakage, very similar to that on @entity941 angiography. The right eye of case 2 showed fewer leakage points on ICG than on @entity941 angiography, compared with case 1. The left eye of case 2 did not show any leakage. Cases 3, 4 and 5 yielded segmental hyperfluorescence, distant from the posterior pole, which could not be identified by @entity941 angiography. This might indicate segmental @entity3193 . There were two types of @entity75 ; all the cases except case 2 showed early hypofluorescence. Hypofluorescent areas corresponding to overlying @entity1713 were seen in the right eye of case 4. @entity1867 , late hypofluorescence, about 200 to 500 um in size appeared throughout the posterior pole in four eyes out of ten. In conclusion, @entity3194 choroidal angiography provides a wider variety of pictures than @entity941 angiography.

title: Exploration of XXXX by infrared choroidal angiography with @entity3194 .

entities_list: @entity75 :: ('MESH:D001927', 'Disease') :: ['hypofluorescent lesions']

entities_list: @entity1713 :: ('MESH:D012163', 'Disease') :: ['retinal detachment']

entities_list: @entity3194 :: ('MESH:D007208', 'Chemical') :: ['indocyanine green']

entities_list: @entity3193 :: ('MESH:D015862', 'Disease') :: ['choroiditis']

entities_list: @entity941 :: ('MESH:D019793', 'Chemical') :: ['fluorescein']

entities_list: @entity7375 :: ('MESH:D014607', 'Disease') :: ['VKH', 'Vogt-Koyanagi-Harada syndrome']

entities_list: @entity1867 :: ('MESH:D008796', 'Disease') :: ['Multiple spots']

answer: @entity7375 :: (MESH:D014607,Disease) :: ['Vogt-Koyanagi-Harada syndrome']


abstract: It is widely accepted that micronutrients have a major function in many periods of @entity1 's life, particularly during pregnancy and lactation. Inadequate stores or intake of micronutrients might have adverse effects both to the mother ( @entity101 , @entity417 , complications of labor) and the fetus ( @entity600 , pre-term delivery, @entity1592 ). The effect of improper nutrition is influenced by gestational age, @entity1032 , or both. Generally, the daily requirements in minerals and trace elements are easily met in @entity1 having a balanced diet. Such diet during pregnancy should provide the recommended daily allowance of all nutrients except elemental @entity68 . Consequently, deficiency states are supposed to be rare in developed countries, and supplementation should be made on an individual basis. On the other hand, @entity3147 during pregnancy might be difficult to detect. Studies from developing countries where micronutrient @entity3147 is common during pregnancy gave us strong evidence that supplementation of certain trace elements and minerals could prevent some of the most severe adverse pregnancy outcomes. While some micronutrients have been studied extensively (e.g. @entity460 , @entity68 , @entity219 , @entity1496 ), much less is known about others. It has been shown that multiple micronutrient @entity942 , are common. Our knowledge about the significance of interactions between micronutrients in relation to pregnancy outcome is limited. The role of these interactions in improving pregnancy outcome need to be investigated more precisely. According to the summarized data, the potential benefits of routine supplementation seem to outweigh any potential adverse reaction that can be attributed to their consumption.

title: Micronutrients in XXXX 's reproductive health: II. Minerals and trace elements.

entities_list: @entity1032 :: ('MESH:D008607', 'Disease') :: ['severity of deficiency']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension']

entities_list: @entity600 :: ('MESH:D000014', 'Disease') :: ['congenital malformations']

entities_list: @entity1592 :: ('MESH:D005317', 'Disease') :: ['intrauterine growth retardation']

entities_list: @entity3147 :: ('MESH:D044342', 'Disease') :: ['malnutrition', 'nutritional deficiencies']

entities_list: @entity460 :: ('MESH:D002118', 'Chemical') :: ['calcium']

entities_list: @entity942 :: ('MESH:D003677', 'Disease') :: ['deficiencies, rather than single deficiencies']

answer: @entity1 :: (9606,Species) :: ['women']


abstract: Some controversy still exists about factors involved in the abnormal circadian pattern of blood pressure (BP) in @entity6 , while prognostic value of non-dipping condition is being increasingly recognised. This study was aimed at evaluating the relative influence of @entity4148 ( @entity4148 ) and albumin excretion on 24-h BP profile in type 1 and type 2 @entity6 . We measured @entity4148 cardiovascular tests, 24-h ambulatory BP, and urinary albumin excretion rate (UAE) in 47 type 1 and 34 type 2 normotensive non-proteinuric @entity6 @entity1 . In type 1 @entity6 @entity1 day-night differences (Delta) in systolic and diastolic BP were lower in those with @entity4148 than in those without (3 +/- 9 vs 10 +/- 6%, P < 0.01, and 8 +/- 9 vs 16 +/- 6%, P < 0.001), and in univariate regression analysis they were inversely related to both autonomic score, index of degree of @entity4148 (r = -0.61, P < 0.001 and r = -0.65, P < 0.001), and to 24-h UAE (r = -0.39, P < 0.01 and r = -0.46, P < 0.001). In type 1 @entity6 @entity1 @entity4148 was also associated with lower nocturnal decrease in UAE ( @entity1 with @entity4148 vs without @entity4148 : -37 +/- 214 vs 49 +/- 37%, P < 0.05), and with a stronger relationship between simultaneous 24-h UAE and 24-h BP (for systolic BP @entity1 with @entity4148 vs without @entity4148 : r = 0.62, P < 0.01 vs r = 0.28, NS). In type 2 @entity6 @entity1 Delta systolic BP was reduced in @entity1 with @entity4148 compared to those without (4 +/- 7 vs 10 +/- 4%, P < 0.01), and it was related only to autonomic score (r = -0.42, P < 0.01). Using a stepwise regression analysis, in type 1 @entity6 @entity1 autonomic score was the variable of primary importance for Delta BP, while in type 2 @entity6 @entity1 it was the unique determinant not only of Delta systolic BP but also of 24-h systolic BP. In conclusion, @entity4148 is the pivotal factor of blunted nocturnal fall in BP in both type 1 and type 2 @entity6 @entity1 . In type 1 @entity6 @entity1 @entity4148 is associated with attenuated circadian pattern of @entity633 and with a steeper relationship between @entity633 and BP, in type 2 @entity6 @entity1 @entity4148 is the only factor related to elevated 24-h BP levels. Longitudinal studies are needed to establish the potential role of @entity5433 as a progression promoter for @entity8 and @entity101 in type 1 and type 2 @entity6 respectively.

title: Factors determining the 24-h blood pressure profile in normotensive XXXX with type 1 and type 2 @entity6 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity8 :: ('MESH:D007674', 'Disease') :: ['nephropathy']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetic', 'diabetes']

entities_list: @entity633 :: ('MESH:D000419', 'Disease') :: ['albuminuria']

entities_list: @entity4148 :: ('MESH:D001342', 'Disease') :: ['autonomic neuropathy', 'AN']

entities_list: @entity5433 :: ('MESH:C563939', 'Disease') :: ['autonomic dysfunction']

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: The reaction of secretory epithelium and myoepithelial cells in the alveoli to hand milking and i.v. injection of @entity398 and @entity2661 was studied in lactating @entity1237 . The reaction of secretory cells was assessed by changes in the transepithelial (blood-milk) @entity841 ( @entity841 ), and the contractile reaction of myoepithelial cells by the growth of @entity551 ( @entity551 ). The initial value of @entity841 was 24.6 +/- 0.6 mV, that of @entity551 3.32 +/- 0.08 kPa (24.9 +/- 0.6 mmHg). Milking and @entity398 administration caused a rise in @entity841 and an increase in @entity551 . After @entity1063 and adrenaline injections two-phase @entity841 changes and a short-term rise in @entity551 were recorded. @entity3044 , a beta-agonist, caused a rise in @entity841 but did not affect @entity551 . @entity2647 , an alpha-agonist, caused two-phase and one-phase changes in @entity841 . Simultaneously, a rise in @entity551 was recorded. The results show that the reaction of the mammary gland to the substances administered is complex. Myoepithelial and secretory cells respond differently to short-term rises in the level of mediators and hormones in the blood.

title: Transepithelial XXXX in the @entity1237 mammary gland and its change during hand milking, and administration of @entity398 and @entity2661 .

entities_list: @entity398 :: ('MESH:D010121', 'Chemical') :: ['oxytocin']

entities_list: @entity841 :: ('MESH:C537245', 'Disease') :: ['potential difference', 'PD']

entities_list: @entity2647 :: ('MESH:D010656', 'Chemical') :: ['Phenylephrine']

entities_list: @entity3044 :: ('MESH:D007545', 'Chemical') :: ['Isoproterenol']

entities_list: @entity1063 :: ('MESH:D009638', 'Chemical') :: ['noradrenaline']

entities_list: @entity2661 :: ('MESH:D002395', 'Chemical') :: ['catecholamines']

entities_list: @entity551 :: ('MESH:D007022', 'Disease') :: ['intramammary pressure', 'IP']

answer: @entity841 :: (MESH:C537245,Disease) :: ['potential difference']


abstract: BACKGROUND CONTEXT: @entity5697 ( @entity5697 ) is one of the defining features of @entity1652 ( @entity1652 ). Despite the well-established criteria, clinical and paraclinical features, the disease is often misdiagnosed and erroneously treated. PURPOSE: We report on a case of @entity5697 in a @entity1 with spatially limited @entity1652 spectrum disorder that was misdiagnosed as @entity4097 and underwent spinal cord biopsy. STUDY DESIGN: A 43-year-old female @entity1 is described. METHODS: The @entity1 developed @entity508 over 1 week. Spinal cord magnetic resonance imaging (MRI) revealed @entity5697 , and she was treated with @entity230 and recovered. Nine months later, her condition worsened and repeat spinal cord MRI was interpreted as a large intramedullary @entity5 in the cervical region with irregular postcontrast enhancement. Biopsy revealed @entity17 . Cerebrospinal fluid (CSF) analysis revealed positive oligoclonal IgG bands, and serum was positive for @entity1652 -IgG antibody. RESULTS: The @entity1 was diagnosed with spatially limited @entity1652 spectrum disorder, treated with plasma exchange, high-dose @entity288 , and @entity786 , and with good recovery. CONCLUSIONS: The factors favoring inflammatory @entity5697 are acute or subacute onset of clinical symptoms, positive oligoclonal bands in the CSF, positive @entity1652 -IgG or other antibodies, and brain MRI showing demyelinating lesions. Postcontrast axial MRI sequences of the spinal cord can also be helpful. In doubtful situations, a trial of therapy and follow-up MRI a month later might be a more prudent approach if the @entity1 is not rapidly deteriorating.

title: XXXX versus transverse myelitis.

entities_list: @entity5697 :: ('MESH:D009188', 'Disease') :: ['Longitudinally extensive transverse myelitis', 'LETM']

entities_list: @entity17 :: ('MESH:D003711', 'Disease') :: ['demyelination']

entities_list: @entity1652 :: ('MESH:D009471', 'Disease') :: ['NMO', 'neuromyelitis optica']

entities_list: @entity508 :: ('MESH:D009128', 'Disease') :: ['spastic tetraparesis']

entities_list: @entity786 :: ('MESH:D003520', 'Chemical') :: ['cyclophosphamide']

entities_list: @entity4097 :: ('MESH:D013120', 'Disease') :: ['spinal cord tumor']

entities_list: @entity230 :: ('MESH:D013256', 'Chemical') :: ['steroids']

entities_list: @entity288 :: ('MESH:D000305', 'Chemical') :: ['corticosteroids']

answer: @entity4097 :: (MESH:D013120,Disease) :: ['Spinal cord tumor']


abstract: INTRODUCTION: With the increasing use of intravitreal administration of corticosteroids in macular @entity4 , @entity479 -induced intraocular pressure (IOP) rise is becoming an emergent issue. However, for @entity1 in whom intravitreal @entity230 are indicated, there are no specific recommendations for IOP monitoring and management after intravitreal administration of corticosteroids. METHOD: An expert panel of European ophthalmologists reviewed evidence on @entity228 -induced IOP elevation. The objective of the panel was to propose an algorithm based on available literature and their own experience for the monitoring and management of corticosteroid-induced IOP elevation, with a focus on @entity6 @entity1 . RESULTS: Data from trials including @entity6 @entity1 with a rise of IOP after intravitreal @entity479 administration indicate that IOP-lowering medical treatment is sufficient for a large majority of @entity1 ; only a small percentage underwent laser trabeculoplasty or filtering filtration surgery. A 2-step algorithm is proposed that is based on the basal value of IOP and evidence for @entity726 . The first step is a risk stratification before treatment. @entity1 normotensive at baseline (IOP   <=  21  mmHg), do not require additional baseline diagnostic tests. However, @entity1 with baseline @entity2790 ( @entity2790 ) (IOP  >  21 mmHg) should undergo baseline imaging and visual field testing. The second step describes monitoring and treatment after @entity479 administration. During follow-up, @entity1 developing @entity2790 should have baseline and periodical imaging and visual field testing; IOP-lowering treatment is proposed only if IOP is >25  mmHg or if diagnostic tests suggest developing @entity726 . CONCLUSION: The management and follow-up of @entity2790 following intravitreal corticosteroid injection is similar to that of primary @entity2790 . If @entity2790 develops, IOP is controlled in a large proportion of @entity1 with standard IOP treatments. The present algorithm was developed to assist ophthalmologists with guiding principles in the management of corticosteroid-induced IOP elevation. FUNDING: Alimera Sciences Limited.

title: Elevated Intraocular Pressure After Intravitreal XXXX Injection in Diabetic Macular Edema: Monitoring and Management.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetic']

entities_list: @entity228 :: ('CHEBI:50858', 'Chemical') :: ['corticosteroid']

entities_list: @entity726 :: ('MESH:D005901', 'Disease') :: ['glaucoma']

entities_list: @entity2790 :: ('MESH:D009798', 'Disease') :: ['OHT', 'ocular hypertension']

answer: @entity479 :: (D013256,Chemical) :: ['Steroid']


abstract: Cellular junctions are essential to the normal functioning of the endothelium and control angiogenesis, tissue leak, and @entity32 . From a screen of micro RNAs (miRNAs) altered in in vitro angiogenesis, we selected a subset predicted to target junctional molecules. @entity42875 was rapidly downregulated upon stimulation of in vitro angiogenesis, and its level of expression is reduced in neovessels in vivo. The downregulation of @entity42875 was essential for angiogenesis because ectopic expression of @entity42875 blocked capillary tube formation and angiogenesis. @entity42875 targets the junctional, endothelial-specific cadherin, @entity7112 . Consistent with this, vascular permeability to vascular endothelial growth factor in @entity19 is reduced by administration of a general miR-27 inhibitor. To determine that @entity7112 was the dominant target of @entity42875 function, we used a novel technology with "Blockmirs," inhibitors that bind to the miR-27 binding site in @entity7112 . The Blockmir @entity42876 demonstrated specificity for @entity7112 and inhibited vascular leak in vitro and in vivo. Furthermore, @entity42876 reduced @entity4 , increased capillary density, and potently enhanced recovery from @entity63 in @entity19 . The Blockmir technology offers a refinement in the use of miRNAs, especially for therapy. Further, targeting of endothelial junctional molecules by miRNAs has clinical potential, especially in diseases associated with vascular leak.

title: Regulation of vascular leak and recovery from @entity63 by general and XXXX -restricted miRNA antagonists of miR-27.

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation']

entities_list: @entity63 :: ('MESH:D007511', 'Disease') :: ['ischemic limb injury']

answer: @entity7112 :: (12562(Tax:10090),Gene) :: ['VE-cadherin']


abstract: The accessory sex gland (ASG) is an important component of the male reproductive system, which functions to enhance the fertility of spermatozoa during male reproduction. Certain proteins secreted by the ASG are known to bind to the spermatozoa membrane and affect its function. The ASG gene expression profile in @entity21397 ( @entity21397 ) has not been extensively studied, and limited genetic research has been conducted on this species. The advent of high-throughput sequencing technologies enables the generation of genomic resources within a short period of time and at minimal cost. In the present study, we performed de novo transcriptome sequencing to produce a comprehensive transcript dataset for the ASG of @entity24334 using Illumina sequencing technology. This analysis yielded a total of 33,221,284 sequencing reads, including 2.6 Gb of total @entity2036 . Reads were assembled into 85,913 contigs (average 218 bp), or 58,567 scaffold sequences (average 292 bp), that identified 37,955 unigenes (average 385 bp). We assembled all unigenes and compared them with the published testis transcriptome from @entity24334 . In order to identify which genes may be involved in ASG function, as it pertains to modification of spermatozoa, we compared the ASG and testis transcriptome of @entity24334 . Our analysis identified specific genes with both higher and lower tissue expression levels in the two tissues, and the functions of these genes were analyzed to elucidate their potential roles during maturation of spermatozoa. Availability of detailed transcriptome data from ASG and testis in @entity24334 can assist our understanding of the molecular mechanisms involved with spermatozoa conservation, transport, maturation and capacitation and potentially acrosome activation.

title: Comparative transcriptome analysis of the accessory sex gland and testis from the @entity21397 ( XXXX ).

entities_list: @entity21397 :: ('95602', 'Species') :: ['Eriocheir sinensis', 'Chinese mitten crab']

entities_list: @entity2036 :: ('MESH:D009711', 'Chemical') :: ['nucleotides']

answer: @entity21397 :: (95602,Species) :: ['Eriocheir sinensis']


abstract: Genetic predisposition plays a major role in the etiology of idiopathic @entity302 . The common @entity302 syndromes display a complex pattern of inheritance, with an unknown number of genes contributing to @entity410 susceptibility. During the last decade linkage studies have narrowed down several candidate regions for susceptibility loci of idiopathic @entity302 . Several lines of evidence point to the existence of an @entity302 susceptibility gene on chromosome 15q14. Evidence for linkage to this region has thus been reported for @entity3149 , common subtypes of @entity3762 ( @entity3762 ), in addition to the EEG trait 'centrotemporal spikes' in families with @entity1654 . The chromosomal region 15q14 harbours several candidate genes that are involved in the regulation of neuronal excitability. One of the most promising candidate genes is the brain-expressed @entity4337 cotransporter @entity42667 , given that this class of ion transporter has been implicated in the regulation of neuronal @entity2865 activity. We therefore performed a mutation analysis of @entity42667 in the index @entity1 of 23 @entity3762 -families as well as of 16 families with @entity1654 which where selected by positive evidence for linkage to D15S165. Four novel single @entity377 exchanges (SNPs) were identified, none of which change the coding sequence. These results do not support a major role for @entity42667 in the etiology of @entity1654 or common subtypes of @entity3762 .

title: Mutation analysis of the XXXX cotransporter @entity42667 ( @entity42667 ) in rolandic and @entity3762 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity377 :: ('CHEBI:36976', 'Chemical') :: ['nucleotide']

entities_list: @entity1654 :: ('MESH:D019305', 'Disease') :: ['rolandic epilepsy']

entities_list: @entity302 :: ('MESH:D004827', 'Disease') :: ['epilepsies', 'epilepsy']

entities_list: @entity3149 :: ('MESH:D020190', 'Disease') :: ['juvenile myoclonic epilepsy']

entities_list: @entity2865 :: ('CHEBI:17996', 'Chemical') :: ['chloride']

entities_list: @entity3762 :: ('MESH:C562694', 'Disease') :: ['idiopathic generalized epilepsy', 'IGE']

entities_list: @entity4337 :: ('MESH:D011189', 'Chemical') :: ['potassium chloride']

answer: @entity4337 :: (MESH:D011189,Chemical) :: ['potassium chloride']


abstract: OBJECTIVE: To develop a scoring algorithm and evaluate the reliability and validity of scores from the @entity1 and Adolescent Trial for Cardiovascular Health (CATCH) Food Checklist ( @entity25938 ) as measures of total fat, saturated fat, and @entity1372 intake in middle school students. DESIGN: Randomized, controlled trial in which @entity1 were assigned to 1 of 3 study protocols that varied the order of @entity25938 and 24-hour dietary recall administration. Criterion outcomes were percent energy from total fat, percent energy from saturated fat, and @entity1372 intake in milligrams. SUBJECTS/SETTING: A multiethnic sample (33% ethnic and racial minorities) of 365 seventh-grade students from 8 schools in 4 states. STATISTICAL ANALYSES: Multivariable regression models were used to calibrate the effects of individual food checklist items; bootstrap estimates were used for cross-validation; and kappa statistics, Pearson correlations, t tests, and effect sizes were employed to assess reliability and validity. RESULTS: The median same-day test-retest reliability kappa for the 40 individual @entity25938 food items was 0.85. With respect to item validity, the median kappa statistic comparing student choices to those identified by staff dietitians was 0.54. Test-retest reliability coefficients ranged from 0.84 to 0.89 for @entity25938 total nutrient scores. Correlations between @entity25938 scores and 24-hour recall values were 0.36 for total fat, 0.36 for saturated fat, and 0.34 for @entity1372 ; @entity25938 scores were consistent with hypothesized gender differences in nutrient intake. APPLICATIONS/CONCLUSIONS: The @entity25938 is a reliable and valid tool for measuring fat, saturated fat, and @entity1372 intake in middle school students. Its brevity and ease of administration make the @entity25938 a cost-effective way to measure middle school students' previous day's intake of selected nutrients in school surveys and intervention studies.

title: Reliability and validity of the XXXX and Adolescent Trial for Cardiovascular Health (CATCH) Food Checklist: a self-report instrument to measure fat and @entity1372 intake by middle school students.

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'Child']

answer: @entity1 :: (9606,Species) :: ['Child']


abstract: "Bystanders" or lay @entity1 are typically the first caregivers to attend to a victim of out-of-hospital @entity1167 . Astronaut @entity910 ( @entity910 ) play a similar role to bystanders aboard the International Space Station (ISS). Studies have demonstrated the importance of bystander cardiopulmonary resuscitation (BCPR) for @entity1 survival before the arrival of emergency medical care. Recent apprehension from bystanders about the threat of contracting communicable diseases during BCPR, however, has led to the consideration of other ventilation systems such as the bag-valve mask (BVM) and automatic transport ventilators ( @entity11254 ). BVM use is called for during CPR aboard the ISS. This study evaluated the ventilation and compression performance of 40 basic CPR-trained bystanders using either a BVM (adult-sized self-inflating bag with face mask) or an @entity11254 (Model 730 ventilator (M730), Impact Instrumentation, Inc., West Caldwell, NJ). Each two-bystander team gave BCPR to a simulated @entity1167 victim using the 2-breath/15-compression cycle for 4 min and then switched roles for another 4-min interval. Compared to BVM use, the M730 led to significantly (p<0.05) lower number of breaths, smaller tidal volumes, airway flows, airway pressures, volume of gas entering the stomach per breath and chest compressions for the 4-min period. The M730 also enabled a bystander to meet the recommendation of 4-breath and compression cycles per minute as per Guidelines 2000. Lastly, ease-of-use scores were significantly higher for the M730 compared to the BVM. Overall, the data suggest that the M730 improves the quality of performance for a bystander performing BCPR.

title: Comparison of ventilation and chest compression performance by bystanders using the Impact Model 730 ventilator and a conventional bag valve with mask in a model of adult XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patient', 'persons']

entities_list: @entity910 :: ('MESH:D004409', 'Disease') :: ['CMO', 'crew medical officers']

entities_list: @entity1167 :: ('MESH:D006323', 'Disease') :: ['cardiopulmonary arrest']

answer: @entity1167 :: (MESH:D006323,Disease) :: ['cardiopulmonary arrest']


abstract: BACKGROUND: A lower (more caudal) position of the larynx may result in a longer collapsible segment of the upper airway. One could thus hypothesize that the lower the larynx the greater the risk for @entity27 ( @entity27 ). To test this hypothesis, we measured the upper @entity1224 to the level of the vocal cord and the horizontal and vertical segments of the @entity3746 (SVT) using multislice CT scan in Japanese @entity1 with @entity27 . METHODS: We recruited 249 consecutive @entity1 who had polysomnography for suspected @entity27 (age, 47.8    14.8 years; BMI, 24.8    4.3 kg/m(2)). Using CT images, we measured @entity1224 ( @entity1224 ), @entity1224 to vocal cord (ALVC), ALVC- @entity1224 , horizontal segment of SVT (SVTH), and vertical segment of SVT (SVTV). The ratio SVTR (SVTH to SVTV) was calculated. The correlation between these measurements and age, BMI, and AHI were evaluated. RESULTS: @entity1 had a longer ALVC than @entity1 . @entity1224 , ALVC, and SVTR were significantly correlated with age and AHI in all @entity1 . Logistic regression analysis showed that ALVC > 0.24 (OR, 4.2; CI, 2.3-7.6) and BMI > 25 (OR, 4.8; CI, 2.7-8.5) were significant variables predicting AHI > 30. Even after controlling for BMI, the effect of ALVC was still significant. CONCLUSIONS: The laryngeal position is lower in @entity1 than @entity1 . Aging is associated with a lower laryngeal position, and a longer ALVC is independently associated with @entity27 severity in Japanese @entity1 . We conclude that both laryngeal descent and BMI may be risk factors for @entity27 .

title: Is laryngeal descent associated with increased risk for XXXX ?

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients', 'Men', 'men']

entities_list: @entity3746 :: ('MESH:D014826', 'Disease') :: ['supralaryngeal vocal cord tract']

entities_list: @entity27 :: ('MESH:D020181', 'Disease') :: ['obstructive sleep apnea', 'OSA']

entities_list: @entity1224 :: ('MESH:D000402', 'Disease') :: ['AL', 'airway length']

answer: @entity27 :: (MESH:D020181,Disease) :: ['obstructive sleep apnea']


abstract: BACKGROUND: @entity1109 ( @entity1109 ) are highly prevalent and are associated with frequent health care use (HCU). @entity1109 frequently co-occur with @entity146 . With this study we examined the longitudinal association between @entity1109 and HCU over 2  years and the influence of @entity308 and @entity1314 traits on this association. METHODS: We analysed follow-up data from 2045 to 2981 @entity1 from the Netherlands Study of @entity308 and @entity148 (NESDA), a multisite cohort study. The study population included @entity1 with a current @entity308 and/or @entity148 , @entity1 with a lifetime risk and/or subthreshold symptoms for @entity308 and/or @entity148 and healthy controls. HCU, measured with the Trimbos and iMTA questionnaire on Costs associated with @entity146 ( @entity2729 ), was operationalized as the number of used medical services and the number of associated contacts. @entity1109 were measured with the Four Dimensional Symptoms Questionnaire, @entity308 with the Composite International Diagnostic Interview and @entity1314 traits with the NEO Five-Factory Inventory. Measurements were taken at baseline, 1 and 2  years follow-up. We used generalized estimating equations (GEE), using HCU at all three measurements as (multivariate) outcome. GEE also takes into account the dependency of observations within @entity1 . RESULTS: @entity1109 were positively associated with HCU over 2  years (medical services: RR 1.020, 95  % CI 1.017-1.022; contacts: RR 1.037, 95  % CI 1.030-1.044). @entity663 and @entity308 had the strongest influence on the associations. After adjustment for these factors, the associations between @entity1109 and HCU weakened, but remained significant (services: RR 1.011, 95  % CI 1.008-1.014; contacts: RR 1.023, 95  % CI 1.015-1.032). CONCLUSIONS: Our results show that @entity1109 were positively associated with HCU over 2  years, even after adjusting for @entity308 and @entity1314 traits.

title: The association between medically unexplained physical symptoms and health care use over two years and the influence of XXXX and @entity1314 traits: a longitudinal study.

entities_list: @entity1 :: ('9606', 'Species') :: ['participants']

entities_list: @entity308 :: ('MESH:D003866', 'Disease') :: ['Depression', 'depressive', 'depressive and anxiety disorders', 'depression']

entities_list: @entity146 :: ('MESH:D001523', 'Disease') :: ['psychiatric disorders', 'Psychiatric illness']

entities_list: @entity1109 :: ('MESH:D012678', 'Disease') :: ['Medically unexplained physical symptoms', 'MUPS']

entities_list: @entity148 :: ('MESH:D001008', 'Disease') :: ['Anxiety', 'anxiety disorder', 'anxiety disorders']

entities_list: @entity663 :: ('MESH:C564323', 'Disease') :: ['Neuroticism']

entities_list: @entity1314 :: ('MESH:D010554', 'Disease') :: ['personality']

answer: @entity308 :: (MESH:D003866,Disease) :: ['depressive and anxiety disorders']


abstract: Oxidative stress may cause various @entity528 and modulate responses to many centrally acting drugs. This study examines the effects of oxidative stress produced by @entity273 ( @entity274 ) on sedation induced by @entity3175 or @entity4763 as assessed in 7-14 day-old chicks. Day-old chicks were provided with either plane tap water (control group) or @entity274 in tap water as 0.5% v/v drinking solution for two weeks in order to produce oxidative stress. Spectrophotometric methods were used to determine @entity2041 and @entity1234 concentrations in plasma and whole brain. Drug-induced sedation in the chicks was assessed by monitoring the occurrence of signs of sedation manifested as drooping of the head, closed eyelids, reduced motility or immotility, @entity393 calls, and recumbency. The latency to onset of sedation and its duration were also recorded. @entity274 treatment for two weeks significantly decreased @entity2041 and increased @entity1234 concentrations in plasma and whole brain of the chicks on days 7, 10 and 14 as compared with respective age-matched control groups. @entity274 decreased the median effective doses of @entity3175 and @entity4763 for the induction of sedation in chicks by 46% and 63%, respectively. Injection of @entity3175 at 2.5, 5 and 10 mg/kg, i.m. or @entity4763 at 2, 4 and 8 mg/kg, i.m. induced sedation in both control and @entity274 -treated chicks in a dose dependent manner, manifested by the above given signs of sedation. @entity274 significantly decreased the latency to onset of sedation in chicks treated with @entity3175 at 5 and 10 mg/kg, increased the duration of sedation and prolonged the total recovery time in comparison with respective non-stressed control chicks. A similar trend occurred with @entity4763 in the @entity274 -treated chicks, though the differences from control counterparts did not attain the statistical significance, except for the recovery time of the lowest dose of the drug. The data suggest that @entity274 -induced oxidative stress sensitizes the chicks to the depressant action of the sedatives @entity3175 and @entity4763 . Further studies are needed to examine the potential role of oxidative stress in modulating the actions of therapeutic agents on the brain.

title: Effects of XXXX on @entity3175 and @entity4763 sedation in chicks.

entities_list: @entity3175 :: ('MESH:D003975', 'Chemical') :: ['diazepam']

entities_list: @entity2041 :: ('MESH:D005978', 'Chemical') :: ['glutathione']

entities_list: @entity4763 :: ('MESH:D014991', 'Chemical') :: ['xylazine']

entities_list: @entity273 :: ('MESH:D006861', 'Chemical') :: ['hydrogen peroxide']

entities_list: @entity1234 :: ('MESH:D008315', 'Chemical') :: ['malondialdehyde']

entities_list: @entity393 :: ('MESH:D034381', 'Disease') :: ['decreased distress']

entities_list: @entity528 :: ('MESH:D009410', 'Disease') :: ['neuronal dysfunctions']

answer: @entity273 :: (MESH:D006861,Chemical) :: ['hydrogen peroxide']


abstract: The expression of the positively charged @entity1 protein secretory leukocyte protease inhibitor ( @entity9511 ) in @entity526 causes severe cellular @entity137 . After induction of @entity9511 synthesis in a high-level-expression strain, SGE61, the growth of the strain is arrested and total protein and RNA synthesis rates decline by 60 to 70%. The mechanism of @entity9511 -mediated inhibition of macromolecular synthesis was examined in cell-free transcription-translation systems. @entity9511 proved to be a potent inhibitor of translation in vitro. When @entity9511 was added to translation reactions at @entity9511 /mRNA ratios attained during maximal @entity9511 accumulation in SGE61, translation of a test mRNA was inhibited by 75%. The mechanism of translation inhibition was deduced from in vitro experiments showing that @entity9511 bound to mRNA and interfered with the interaction of RNA-metabolizing enzymes, such as RNase. In addition, @entity9511 bound to DNA in vitro, but transcription was not inhibited as strongly in cell-free reactions as it was in SGE61. Similar nucleic acid-binding and translation inhibition properties were displayed in vitro by another basic protein, @entity1573 egg white lysozyme, but were not displayed by the relatively acidic protein bovine serum albumin. On the basis of these results, we concluded that @entity9511 binds to nucleic acids via charge interactions and inhibits translation by competing with ribosomes for binding to mRNA. Since @entity9511 -mRNA and @entity9511 -DNA binding occurred at @entity9511 /mRNA and @entity9511 /DNA ratios existing in SGE61, nucleic acid binding may contribute to the @entity137 of @entity9511 to @entity526 . These results indicate that, in general, high-level expression of basic recombinant proteins in @entity526 may be problematic.

title: Secretory leukocyte protease inhibitor binding to mRNA and DNA as a possible cause of @entity137 to XXXX .

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity']

entities_list: @entity526 :: ('562', 'Species') :: ['Escherichia coli', 'E. coli']

answer: @entity526 :: (562,Species) :: ['Escherichia coli']


abstract: Two experiments were conducted to determine AA digestibility and the concentration of DE and ME in 5 sources of @entity1460 meal (SBM). The 5 sources included @entity4315 -extracted SBM produced from high-protein @entity1460 (SBM- @entity4306 ) and conventional @entity1460 (SBM-CONV), and mechanically extruded-expelled SBM produced from high-protein @entity1460 (EE-SBM- @entity4306 ), low-oligosaccharide @entity1460 (EE-SBM-LO), and conventional @entity1460 (EE-SBM-CONV). Five diets that each contained 1 source of SBM and a N-free diet were used in Exp. 1 to determine AA digestibility in each meal. Twelve growing barrows (initial BW: 67.7 +/- 1.34 kg) were allotted to a replicated 6 x 6 Latin square design with 6 periods and 6 diets in each square. Each period lasted 7 d, and ileal digesta were collected on d 6 and 7 of each period. Results of the experiment showed that the @entity4628 ( @entity4628 ) of all AA except Trp was similar for SBM- @entity4306 and SBM-CONV, but EE-SBM- @entity4306 and EE-SBM-LO had greater (P < 0.05) @entity4628 of His, Ile, Lys, Thr, and @entity2596 than EE-SBM-CONV. The @entity4628 of all indispensable AA in EE-SBM- @entity4306 was greater (P < 0.05) than in SBM- @entity4306 . The @entity4628 of @entity534 , Ile, Leu, and @entity815 in EE-SBM-CONV was greater (P < 0.05) than in SBM-CONV, but the @entity4628 of Trp was also greater (P < 0.05) in SBM-CONV than in EE-SBM-CONV. Experiment 2 was conducted to measure DE and ME in the same 5 sources of SBM as used in Exp. 1. Forty-eight growing barrows (initial BW: 38.6 +/- 3.46 kg) were placed in metabolism cages and randomly allotted to 6 diets with 8 replicates per diet. A @entity4336 -based diet and 5 diets based on a mixture of @entity4336 and each source of SBM were formulated. Urine and feces were collected during a 5-d collection period, and values for DE and ME in each source of SBM were calculated using the difference procedure. Results showed that the ME in SBM- @entity4306 tended to be greater (P = 0.10) than in SBM-CONV (4,074 vs. 3,672 kcal/kg of @entity3918 ). The ME in EE-SBM- @entity4306 also tended to be greater (P = 0.10) than in EE-SBM-CONV and in EE-SBM-LO (4,069 vs. 3,620 and 3,721 kcal/kg of @entity3918 ), but there was no difference in ME between extracted and extruded-expelled meals. It is concluded that SBM- @entity4306 has a greater feeding value than SBM-CONV because of greater concentrations of digestible AA and ME. Likewise, EE-SBM-LO has a greater concentration of most indispensable AA than EE-SBM-CONV, but the concentration of ME is similar in these 2 meals. Results of this experiment also showed that AA digestibility values in extruded-expelled SBM are greater than in @entity4315 -extracted SBM.

title: Amino acid digestibility and concentration of digestible and metabolizable energy in XXXX meal produced from conventional, high-protein, or low-oligosaccharide varieties of @entity1460 and fed to growing pigs.

entities_list: @entity4628 :: ('MESH:D007077', 'Disease') :: ['SID', 'standardized ileal digestibility']

entities_list: @entity1460 :: ('3847', 'Species') :: ['soybean', 'soybeans']

answer: @entity1460 :: (3847,Species) :: ['soybean']


abstract: PURPOSE: The goal of our study was to investigate the associations between surgical delay, @entity158 and meniscus, and articular @entity1844 seen at the time of ACL reconstruction. METHODS: One hundred and sixty-two consecutive @entity1 who had received ACL reconstruction were recruited. The preoperative International Knee Documentation Committee (IKDC) questionnaires, and cartilage and @entity75 seen at the time of surgery were analysed. RESULTS: @entity1 with surgery within 12 months were less likely to have @entity130 (59.8/77.4 %, p = 0.032), and the @entity130 was more likely to be salvageable. (56.3/36.0 %, p = 0.042). @entity1 with @entity937 larger than 10 mm had higher @entity158 intensity than tear <10 mm (mean 6.8/8.2, p = 0.007). @entity1 older than 35 years of age were more likely to suffer from @entity1844 (76.4/39.1 %, p = 0.004). @entity1 with @entity1844 had longer surgical delay (mean 18.9/12.1 months, p = 0.033). The presence of @entity937 increased the risk of @entity1844 (p = 0.038, OR = 2.14). @entity1 with @entity1844 had a greater @entity158 frequency (mean 6.9/7.7, p = 0.048). Moderate correlation was found between the size of cartilage lesion and the frequency of @entity158 (p = 0.013). CONCLUSIONS: Increased surgical delay was associated with an increased incidence of meniscus and articular @entity1844 in @entity1 suffering from ACL tear; also, the meniscus was less likely to be salvageable. The presence of @entity1844 was associated with an increased frequency of @entity158 . Size of meniscal and @entity1844 was significantly associated with @entity158 .

title: Delay in ACL reconstruction is associated with more severe and @entity158 meniscal and XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity1844 :: ('MESH:D002357', 'Disease') :: ['cartilage injury', 'cartilage lesions', 'cartilage injuries']

entities_list: @entity937 :: ('MESH:D012167', 'Disease') :: ['meniscal tear']

entities_list: @entity75 :: ('MESH:D001927', 'Disease') :: ['meniscal lesions']

entities_list: @entity130 :: ('MESH:D014947', 'Disease') :: ['meniscus injury']

answer: @entity130 :: (MESH:D014947,Disease) :: ['chondral injuries']


abstract: BACKGROUND: It is known that cholinergic anti-inflammatory reflex regulates @entity32 in peripheral tissues. Nicotinic @entity934 receptors (nAChRs) are mediators of this anti-inflammatory pathway and also non-neuronal cells express functional nAChrs. A role for a7-subtype @entity934 cholinergic receptor (a7nAChR) in insulin sensitivity improvement has already been shown in rodents both in vivo and in vitro. However, no data are available on a7 @entity6786 expression in @entity1 adipocytes. OBJECTIVE: To investigate the expression and protein content of a7 @entity6786 in @entity1 @entity1386 ( @entity1386 ) and in isolated mature adipocytes. DESIGN: A total of 39 @entity1386 biopsy specimens obtained from @entity28 and normal-weight subjects were used to assess a7 @entity6786 messenger RNA levels and to stimulate a7nAChR with a specific agonist and antagonist in vitro. Additional SATs from eight @entity6 subjects were also studied, before and after a 3-month lifestyle intervention. RESULTS: a7 @entity6786 expression was significantly lower in the @entity1386 of @entity28 subjects compared with that of normal-weight subjects. In mature adipocytes isolated from morbidly @entity28 subjects (body mass index > 40 kg m(-2)), a7 @entity6786 expression was 75% lower compared with adipocytes from normal-weight subjects. In adipocytes of @entity28 subjects, a7 @entity6786 was downregulated also at protein level. In eight @entity6 subjects, a lifestyle intervention (3 months of diet and physical activity) induced a significant @entity353 and an increase in a7nAChR @entity1386 expression. In vitro stimulation of adipocytes with the specific a7nAChR agonist @entity2510 induced a significant anti-inflammatory effect. Furthermore, a similar downregulation of the inflammatory profile, associated with a significant increase in a7 @entity6786 protein level, was observed after @entity670 stimulation. CONCLUSIONS: These results provide evidence that a7nAChR expression levels are significantly decreased in @entity28 subjects, and that this receptor modulates inflammatory gene expression in @entity1 adipocytes. The upregulation of a7nAChR by @entity670 stimulation opens new insights for the management of low-grade @entity32 linked to @entity1 @entity28 .

title: The nicotinic @entity934 receptor a7 in subcutaneous mature adipocytes: downregulation in @entity1 @entity28 and modulation by diet-induced XXXX .

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation']

entities_list: @entity353 :: ('MESH:D015431', 'Disease') :: ['weight loss']

entities_list: @entity28 :: ('MESH:D009765', 'Disease') :: ['obese', 'obesity']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['non-diabetic obese']

entities_list: @entity670 :: ('MESH:D019833', 'Chemical') :: ['genistein']

entities_list: @entity1386 :: ('MESH:D018205', 'Disease') :: ['subcutaneous adipose tissue', 'SAT']

entities_list: @entity934 :: ('MESH:D000109', 'Chemical') :: ['acetylcholine']

answer: @entity353 :: (MESH:D015431,Disease) :: ['weight loss']


abstract: PURPOSE: Recent reports suggest an increasing incidence of CNS @entity3 in @entity1 with @entity43 . We reviewed our experience in the management of brain @entity3 from @entity43 and merged our results with those of several other series reported in the literature to determine prognostic factors and the role of chemotherapy, @entity1161 , and surgery. @entity1 AND METHODS: From 1977 to 1990, 15 of 795 @entity1 who were treated for @entity43 at Duke University developed brain @entity3 . Fourteen of the @entity1 were treated for their brain @entity3 ; this included @entity1161 ( @entity1161 ; four), surgery and @entity1161 (one), @entity1161 and systemic chemotherapy (six), and all three treatment modalities (three). A meta-analysis was performed that combined the data from the current series with those of several recent clinical series that reviewed @entity1 with brain @entity3 from @entity43 (67 @entity1 total) to elucidate the impact of treatment and extent of disease on survival. RESULTS: In the current series, median survival (MS) after the diagnosis of brain @entity3 was 9 months. For the combined series, MS was 5 months. Thirteen @entity1 who were treated with whole-brain @entity1161 and systemic chemotherapy (MS, 7 months), 10 @entity1 who were treated with @entity1161 and surgery (MS, 10 months), and nine @entity1 who were treated with all three modalities (MS, 16.5 months) had significantly longer survival than 19 @entity1 who were treated with @entity1161 alone (MS, 3 months) (P = .05, P = .01, and P < .001, respectively). In a multivariate analysis, the only variable that provided prognostic information was treatment, namely the addition of systemic chemotherapy or surgery to @entity1161 for the treatment of brain @entity3 . CONCLUSION: Multimodal treatment of @entity1 with brain @entity3 from @entity43 can result in significant palliation.

title: Improved palliation of cerebral @entity3 in XXXX using a combined modality approach including @entity1161 , chemotherapy, and surgery.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS']

entities_list: @entity1161 :: ('MESH:D011832', 'Disease') :: ['radiation therapy', 'RT']

entities_list: @entity43 :: ('MESH:D010051', 'Disease') :: ['ovarian carcinoma', 'ovarian cancer', 'epithelial ovarian cancer']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastases']

answer: @entity43 :: (MESH:D010051,Disease) :: ['epithelial ovarian cancer']


abstract: STUDY OBJECTIVES: The purpose of this report is to review our experience with @entity2 ( @entity2 ) at the Walter Reed Army Medical Center, Washington, DC, and to determine the outcome of our surgical management of this complex problem. @entity1 AND METHODS: The data from the Lung Cancer Registry on @entity1 with @entity2 from January 1984 to December 1995 were reviewed. We used the criteria of Martini and Melamed modified by Antakli for the diagnosis of synchronous and metachronous @entity2 . Survival probabilities were calculated by the Kaplan-Meier actuarial method with the dates of resection as the starting point and included deaths from all causes. The log rank test was used to compare survival rates between groups and Wilcoxon rank sum test was used to compare the intervals between the first and the second @entity5 . A p value of 0.05 was considered statistically significant. RESULTS: Fifty-two @entity1 , consisting of 51 @entity1 who had "curative" pulmonary resections and 1 @entity1 who had radiation therapy for previous primary @entity2 , developed second or third primary @entity2 . Thirty-seven @entity1 developed @entity5 within 1 to 15 years of the first operation (median, 24 months) while 15 @entity1 had @entity5 (10 unilateral, 5 bilateral). The probability of @entity5 -free interval among @entity1 with @entity5 was 41% at 3 years, 16% at 5 years, and 3% at 10 years. Two of the 36 @entity1 who had pulmonary resection for the second @entity5 died in the perioperative period (operative mortality, 5.6%), and one @entity1 had radiation therapy for the second @entity5 . There were no deaths among @entity1 with @entity5 . The actuarial 5-year survival for second @entity5 was 37% and for @entity5 was 0%. CONCLUSIONS: We conclude that an aggressive surgical approach is safe and justified in most @entity1 with @entity2 , especially @entity1 with @entity5 , while @entity1 with @entity2 have poorer prognosis. The operative morbidity and mortality are acceptable and long-term survival is possible in many @entity1 with metachronous @entity2 .

title: The results of modern surgical therapy for XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'PATIENTS']

entities_list: @entity2 :: ('MESH:D008175', 'Disease') :: ['synchronous lung cancers', 'MPLC', 'multiple primary lung cancers', 'lung cancers', 'lung cancer']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['synchronous cancers', 'metachronous cancers', 'cancer', 'metachronous cancer']

answer: @entity2 :: (MESH:D008175,Disease) :: ['multiple primary lung cancers']


abstract: OBJECTIVE: To assess the efficacy and tolerability of @entity1089 for @entity2146 or @entity716 in @entity1 with @entity303 and @entity304 . METHODS: Multicenter randomized, double-blind, placebo-controlled parallel groups clinical trial involving 40 @entity1 with @entity303 with @entity1832 (n = 23), @entity191 ( @entity191 ) with @entity303 (n = 9), or @entity195 with @entity191 features (n = 8). The main outcome measure for efficacy was change in the Brief Psychiatric Rating Scale (BPRS) from baseline to 10 weeks of therapy. For tolerability it was change in the Unified @entity191 Rating Scale (UPDRS) motor section over the same time period. The trial was confounded by the need for a design change and incomplete recruitment. RESULTS: No significant differences in the primary or secondary outcome measures of efficacy were observed. An unexpectedly large placebo effect, inadequate dosage (mean 120 mg/day), and inadequate power may have contributed to lack of demonstrable benefit. @entity1089 was generally well-tolerated and did not worsen @entity304 , but was associated with a trend toward a decline on a measure of daily functioning. CONCLUSIONS: @entity1089 was well-tolerated and did not worsen @entity304 . Although conclusions about efficacy may be limited, the drug in the dosages used did not show demonstrable benefit for treating @entity2146 or @entity716 in @entity1 with @entity303 and @entity304 . These findings are in keeping with prior studies reporting limited efficacy of various medications for reducing @entity146 in demented @entity1 .

title: @entity1089 for @entity2146 or @entity716 in XXXX with @entity303 and @entity304 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity304 :: ('MESH:D010302', 'Disease') :: ['parkinsonism']

entities_list: @entity146 :: ('MESH:D001523', 'Disease') :: ['behavioral problems']

entities_list: @entity303 :: ('MESH:D003704', 'Disease') :: ['dementia']

entities_list: @entity191 :: ('MESH:D010300', 'Disease') :: ['Parkinson disease', 'PD', 'parkinsonian']

entities_list: @entity1832 :: ('MESH:D020961', 'Disease') :: ['Lewy bodies']

entities_list: @entity2146 :: ('MESH:D011595', 'Disease') :: ['agitation']

entities_list: @entity716 :: ('MESH:D011605', 'Disease') :: ['psychosis']

entities_list: @entity195 :: ('MESH:D000544', 'Disease') :: ['Alzheimer disease']

entities_list: @entity1089 :: ('MESH:C069541', 'Chemical') :: ['quetiapine', 'Quetiapine']

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: PURPOSE: The expression of the major histocompatibility complex class I (MHC-I) in the brain has received considerable interest not only because of its fundamental role in the immune system, but also for its non-immune functions in the context of activity-dependent brain development and plasticity. METHODS: In the present study we evaluated the expression and cellular pattern of MHC-I in focal @entity75 associated with intractable @entity302 . MHC-I expression was studied in @entity302 surgery cases with @entity10067 ( @entity24732 I, n = 6; @entity24732 IIa, n = 6 and @entity24732 IIb, n = 15), @entity2916 ( @entity2916 , cortical tubers; n = 6) or @entity7667 ( @entity7667 ; n = 15) using immunocytochemistry. Evaluation of T lymphocytes with granzyme-B+ granules and albumin immunoreactivity was also performed. RESULTS: All lesions were characterized by MHC-I expression in blood vessels. Expression in both endothelial and microglial cells as well as in neurons ( @entity528 ) was observed in @entity24732 II, @entity2916 and @entity7667 cases. We observed perivascular and parenchymal T lymphocytes (CD8+, T-cytotoxic) with granzyme-B+ granules in @entity24732 IIb and @entity2916 specimens. Albumin extravasation, with uptake in astrocytes, was observed in @entity24732 IIb and @entity7667 cases. CONCLUSIONS: Our findings indicate a prominent upregulation of MHC-I as part of the immune response occurring in @entity75 . In particular, the induction of MHC-I in neuronal cells appears to be a feature of type II @entity24732 , @entity2916 and @entity7667 and may represent an important accompanying event of the immune response, associated with @entity75 , in these developmental lesions.

title: Differential expression of major histocompatibility complex class I in developmental XXXX .

entities_list: @entity75 :: ('MESH:D001927', 'Disease') :: ['glioneuronal lesions', 'blood-brain barrier dysfunction', 'epileptogenic glioneuronal lesions']

entities_list: @entity2916 :: ('MESH:D014402', 'Disease') :: ['tuberous sclerosis complex', 'TSC']

entities_list: @entity302 :: ('MESH:D004827', 'Disease') :: ['epilepsy']

entities_list: @entity10067 :: ('MESH:C537067', 'Disease') :: ['focal cortical dysplasia']

entities_list: @entity7667 :: ('MESH:D018303', 'Disease') :: ['ganglioglioma', 'GG']

entities_list: @entity528 :: ('MESH:D009410', 'Disease') :: ['dysmorphic/dysplastic neurons']

answer: @entity75 :: (MESH:D001927,Disease) :: ['glioneuronal lesions']


abstract: BACKGROUND: @entity1 undergoing hip or knee joint replacement are at risk for @entity1211 for up to twelve weeks postoperatively. We evaluated the efficacy and safety of a prolonged post-hospital regimen of @entity2120 , a low-molecular-weight heparin, in this @entity1 population. METHODS: Following elective total hip or knee replacement, 968 @entity1 received subcutaneous @entity2120 (30 mg twice daily) for seven to ten days, and 873 were then randomized to receive three weeks of double-blind outpatient treatment with either @entity2120 (40 mg once daily) or a placebo. The primary efficacy end point was the prevalence of objectively confirmed @entity1211 or symptomatic @entity1151 during the double-blind phase of treatment. RESULTS: Of the 873 randomized @entity1 , 435 underwent elective total hip replacement and 438 underwent elective total knee replacement. @entity2120 was superior to the placebo in reducing the prevalence of @entity1211 in @entity1 treated with hip replacement: 8.0% (eighteen) of the 224 @entity1 treated with @entity2120 had @entity1211 compared with 23.2% (forty-nine) of the 211 @entity1 treated with the placebo (p < 0.001; odds ratio, 3.62; 95% confidence interval, 2.00 to 6.55; relative risk reduction, 65.5%). @entity2120 had no significant benefit in the @entity1 treated with knee replacement: thirty-eight (17.5%) of the 217 @entity1 treated with @entity2120 had @entity1211 compared with forty-six (20.8%) of the 221 @entity1 treated with the placebo (p = 0.380; odds ratio, 1.24; 95% confidence interval, 0.76 to 2.02; relative risk reduction, 15.9%). Symptomatic @entity1151 developed in three @entity1 , one with a hip replacement and two with a knee replacement; all had received the placebo. There was no significant difference in the prevalence of @entity548 episodes or other types of @entity137 between the @entity2120 and placebo-treated groups. CONCLUSIONS: Prolonging @entity2120 thromboprophylaxis following hip replacement for a total of four weeks provided therapeutic benefit, by reducing the prevalence of @entity1211 , without compromising safety. A similar benefit was not observed in @entity1 treated with knee replacement.

title: Prolonged @entity2120 therapy to prevent XXXX after primary hip or knee replacement. @entity2120 Clinical Trial Group.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['hemorrhagic']

entities_list: @entity1151 :: ('MESH:D011655', 'Disease') :: ['pulmonary embolism']

entities_list: @entity1211 :: ('MESH:D054556', 'Disease') :: ['venous thromboembolic complications', 'venous thromboembolism']

entities_list: @entity2120 :: ('MESH:D017984', 'Chemical') :: ['enoxaparin', 'Enoxaparin']

answer: @entity1211 :: (MESH:D054556,Disease) :: ['venous thromboembolism']


abstract: HISTORY AND PHYSICAL FINDINGS: A 34-year old @entity1 was referred because of persistent low-grade @entity221 and a newly-diagnosed systolic murmur. He complained of atypical @entity662 and dyspnoea on exertion for the past few weeks. STUDIES: Blood analysis revealed an elevated CRP level (67.7 mg/l) along with a @entity24194 , microcytic @entity417 (Hb 122 g/l). Transthoracic echocardiography showed an extracardiac @entity5 compressing the right ventricular outflow tract. Computed tomography (CT) localized the @entity5 in the anterior upper @entity6830 . Subsequently, a biopsy was carried out and revealed a non-seminomatous germ-cell @entity5 . DIAGNOSIS, TREATMENT AND COURSE: The diagnosis having been made the @entity1 received four cycles of chemotherapy according to the BEP-protocol ( @entity1732 - @entity2879 - @entity900 ). The remaining @entity5 was then resected surgically. After additional cycles of chemotherapy two autologous stem cell transplantations were carried out. CONCLUSION: This @entity1 presented initially with symptoms typical of @entity884 . However, the reason for his newly diagnosed systolic murmur and persistent @entity221 was an extracardiac germ cell @entity5 compressing the right ventricular outflow tract.

title: [Uncommon diagnosis in a @entity1 with XXXX and new-onset cardiac murmur].

entities_list: @entity662 :: ('MESH:D002637', 'Disease') :: ['chest pain']

entities_list: @entity24194 :: ('MESH:D000747', 'Disease') :: ['hypochromic']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'tumour']

entities_list: @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin']

entities_list: @entity2879 :: ('MESH:D005047', 'Chemical') :: ['etoposide']

entities_list: @entity1732 :: ('MESH:D001761', 'Chemical') :: ['bleomycin']

entities_list: @entity6830 :: ('MESH:D008479', 'Disease') :: ['mediastinum']

entities_list: @entity884 :: ('MESH:D004696', 'Disease') :: ['endocarditis']

answer: @entity221 :: (MESH:D005334,Disease) :: ['fever']


abstract: OBJECTIVE: To evaluate the phenotype of 15 @entity1 with @entity1717 ( @entity1717 ) and profound @entity393 , known as Homozygous 11p15-p14 @entity3768 (MIM #606528). RESEARCH DESIGN AND METHODS: Prospective clinical follow-up and genetic analysis by direct sequencing, multiplex ligation-dependent probe amplification, and microsatellite markers. RESULTS: Genetic testing identified the previous described homozygous deletion in 11p15, @entity32807 :c.(90+592)_ABCC8:c.(2694-528)del. Fourteen @entity1 had severe @entity1717 demanding near-total pancreatectomy. In one @entity1 with mild, transient @entity4053 and nonautoimmune @entity6 at age 11 years, no additional mutations were found in @entity5448 , @entity5907 , @entity14224 , INS, and @entity8277 . @entity6391 was found in two @entity1 aged 9 and 13 years. No @entity1 had @entity8 . Neuromotor development ranged from normal to severe delay with @entity302 . CONCLUSIONS: The phenotype of Homozygous 11p15-p14 @entity3768 , or @entity1717 , includes any severity of neonatal-onset @entity1717 and severe, @entity1274 . @entity6391 and nonautoimmune @entity6 may occur in adolescence.

title: Heterogeneity in phenotype of @entity1717 : XXXX , @entity6391 , and hyperinsulinemic @entity4053 ranging from severe to mild with conversion to @entity6 .

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'patients', 'patient']

entities_list: @entity8 :: ('MESH:D007674', 'Disease') :: ['enteropathy or renal tubular defects']

entities_list: @entity3768 :: ('MESH:D002872', 'Disease') :: ['Deletion syndrome']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes']

entities_list: @entity4053 :: ('MESH:D007003', 'Disease') :: ['neonatal hypoglycemia']

entities_list: @entity1717 :: ('MESH:D044903', 'Disease') :: ['CHI', 'Usher-CHI syndrome', 'congenital hyperinsulinism']

entities_list: @entity6391 :: ('MESH:D012174', 'Disease') :: ['Retinitis pigmentosa']

entities_list: @entity1274 :: ('MESH:D006319', 'Disease') :: ['sensorineural hearing loss']

entities_list: @entity302 :: ('MESH:D004827', 'Disease') :: ['epilepsy']

entities_list: @entity393 :: ('MESH:D034381', 'Disease') :: ['hearing loss']

answer: @entity393 :: (MESH:D034381,Disease) :: ['hearing loss']


abstract: BACKGROUND: @entity2883 with @entity2883 (GP) is a @entity1333 of unknown etiology that involves small and medium caliber vessels. It is associated with anti neutrophil cytoplasm antibodies (ANCA). It most often affects the respiratory tract and the kidneys and its most important pathologic feature is the presence of necrotizing @entity738 . OBJECTIVES: To detail the features of 15 @entity1 with GP diagnosed in a university referral center. @entity1 AND METHODS: Retrospective study: between 1984 and 2009, 15 @entity1 with GP were diagnosed in our center. Epidemiological, clinical, laboratory test as well as pathologic studies and treatment were retrospectively analyzed. Biopsy diagnosis of GP was considered as an inclusion criterion. RESULTS: Fifteen @entity1 were diagnosed: 12 @entity1 and 3 @entity1 . Mean age at diagnosis: 52.2 years (14-78). 12 @entity1 had a history of smoking. A biopsy was diagnostic in all @entity1 . ANCA were positive in 11 cases, 6 had a cytoplasmic c-ANCA pattern. All @entity1 had @entity358 and seven (40%) had renal involvement. All @entity1 received intravenous glucocorticoids and @entity786 as induction therapy. During the disease progression 5 @entity1 died. CONCLUSIONS: The clinical features of this series do not differ from those described by other authors. However, a history of smoking is more common than expected. Frequently used drugs were glucocorticoids and @entity786 (oral and pulse therapy). The course was usually unfavorable, with outbreaks or complications due to immunosuppression, except for those with limited forms. Immunosuppressive therapy should be maintained indefinitely in most cases.

title: [ @entity2883 with XXXX (Wegener). Description of 15 cases].

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients', 'PATIENTS', 'men']

entities_list: @entity738 :: ('MESH:D006099', 'Disease') :: ['granulomas']

entities_list: @entity1333 :: ('MESH:D014657', 'Disease') :: ['necrotizing vasculitis']

entities_list: @entity786 :: ('MESH:D003520', 'Chemical') :: ['cyclophosphamide']

entities_list: @entity358 :: ('MESH:D008171', 'Disease') :: ['pulmonary involvement']

entities_list: @entity2883 :: ('MESH:D014890', 'Disease') :: ['Granulomatosis', 'polyangiitis']

answer: @entity2883 :: (MESH:D014890,Disease) :: ['polyangiitis']


abstract: CONTEXT: Mutations in the transcription factor @entity23787 have previously been described in association with @entity39997 ( @entity39997 ) as well as isolated defects of the @entity2339 . OBJECTIVE: Given that previous screening was carried out by SSCP detection alone and limited to coding regions, we performed an in-depth genetic analysis of @entity23787 to establish the true contribution of @entity23787 genetic defects to the etiology of @entity4614 . DESIGN: Nonfamilial @entity1 (724) with either @entity39997 (n = 314) or isolated @entity4611 , @entity1781 , or midline @entity16 (n = 410) originally screened by SSCP were rescreened by heteroduplex detection for mutations in the coding and regulatory regions of @entity23787 . In addition, direct sequencing of @entity23787 was performed in 126 @entity1 with @entity4614 from 66 unrelated families and in 11 @entity1 born to consanguineous parents. @entity1 : All @entity1 studied had at least one of the three classical features associated with @entity39997 ( @entity1781 , @entity4614 , midline @entity15407 ). RESULTS: Novel sequence changes identified included a functionally significant heterozygous mutation at a highly conserved residue ( @entity39998 ) in a @entity1 with isolated @entity2338 and @entity854 . The overall incidence of coding region mutations within the cohort was less than 1%. CONCLUSIONS: Mutations within @entity23787 are a rare cause of @entity39997 and @entity4614 . However, the large number of familial @entity1 with @entity39997 in whom no mutations were identified is suggestive of an etiological role for other genetic factors. Furthermore, we have found that within our cohort @entity39997 is associated with a reduced maternal age compared with isolated defects of the @entity2270 .

title: XXXX mutations are an uncommon cause of @entity39997 and @entity4614 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'PATIENTS']

entities_list: @entity15407 :: ('MESH:C566067', 'Disease') :: ['forebrain defects']

entities_list: @entity2338 :: ('MESH:D004393', 'Disease') :: ['GH deficiency']

entities_list: @entity16 :: ('MESH:D009422', 'Disease') :: ['neurological abnormalities']

entities_list: @entity4611 :: ('MESH:D010900', 'Disease') :: ['pituitary dysfunction']

entities_list: @entity4614 :: ('MESH:D007018', 'Disease') :: ['hypopituitarism', 'familial hypopituitarism']

entities_list: @entity2339 :: ('MESH:D007029', 'Disease') :: ['hypothalamic-pituitary axis']

entities_list: @entity1781 :: ('MESH:D009901', 'Disease') :: ['optic nerve hypoplasia']

entities_list: @entity854 :: ('MESH:D018376', 'Disease') :: ['digital abnormalities']

entities_list: @entity39997 :: ('MESH:C531815', 'Disease') :: ['SOD', 'septooptic dysplasia']

entities_list: @entity2270 :: ('MESH:C566610', 'Disease') :: ['hypothalamopituitary axis']

answer: @entity23787 :: (8820,Gene) :: ['HESX1']